Cipla in Licensing Pact With Gilead Sciences for Manufacturing, Distribution of Remdesivir
May 13 2020 - 12:05AM
Dow Jones News
By P.R. Venkat
Cipla Ltd. said it has signed a non-exclusive licensing
agreement with Gilead Sciences Inc. for the manufacturing and
distribution of the investigational medicine, Remdesivir.
The agreement is part of Cipla's efforts to enhance global
access to lifesaving treatments for patients affected by the
Covid-19 pandemic, the Indian-listed pharmaceutical company said
Wednesday.
Remdesivir has been issued an emergency-use authorization by the
U.S. Food and Drug Administration to treat Covid-19 patients.
As part of the agreement, Cipla will be permitted to manufacture
the active pharmaceutical ingredient and finished product, and
market it in 127 countries including India and South Africa under
Cipla's own brand name, the company said.
Cipla will receive the manufacturing know-how from Gilead
Sciences at a commercial scale.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
May 12, 2020 23:50 ET (03:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024